Wegovy Lawsuit 2026: 3,848 Cases Filed as MDL Expands — What Injured Patients Need to Know

The litigation surrounding Wegovy — Novo Nordisk’s blockbuster weight-loss drug — is accelerating in 2026. As of July 1, 2026, the federal multidistrict litigation (MDL) consolidating gastrointestinal injury claims has grown to 3,848 active cases, up from roughly 2,300 a year ago. A separate MDL tracking vision loss injuries has reached 146 cases. And in a striking new development this month, Novo Nordisk itself filed suit against competitor Eli Lilly — escalating the legal and commercial battle surrounding GLP-1 drugs to an entirely new level.

For patients who developed serious complications after taking Wegovy, the expanding litigation signals one thing above all: the window to file is open, but it will not stay open indefinitely.

What the Wegovy Lawsuits Allege

Wegovy is a brand-name injectable medication containing semaglutide — a GLP-1 receptor agonist that slows stomach emptying to reduce appetite and promote weight loss. The same molecule (at different doses) is sold as Ozempic for blood sugar management in Type 2 diabetics.

Plaintiffs in the MDL lawsuits claim that Novo Nordisk knew — or should have known — that Wegovy and similar GLP-1 drugs carry a significantly higher risk of severe gastrointestinal injuries than the company disclosed. The injuries named in these lawsuits include:

• Gastroparesis (stomach paralysis) — the stomach muscles stop functioning properly, causing food to remain undigested for hours or days
• Bowel obstruction and ileus — complete or near-complete blockage of the intestines, often requiring emergency surgery
• Pancreatitis — inflammation of the pancreas, which can be severe and life-threatening
• Gallbladder disease — including gallstones and cholecystitis, sometimes requiring gallbladder removal
• Severe nausea, vomiting, and dehydration — beyond the “mild nausea” described in early marketing materials

The core legal theory is a failure-to-warn claim under products liability law: Novo Nordisk allegedly downplayed these risks in its labeling and marketing, leaving patients and prescribing physicians without the information needed to make informed decisions. The FDA updated Ozempic and Wegovy warning labels in December 2024 to include intestinal blockage and ileus — but for many patients, that warning came too late.

Where the MDL Stands: July 2026

The primary litigation is consolidated in MDL No. 3094, officially titled In re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, in the U.S. District Court for the Eastern District of Pennsylvania. Federal Judge Karen S. Marston is presiding.

As of July 1, 2026, MDL 3094 has 3,848 active personal injury lawsuits — an increase of more than 1,500 cases since August 2025 alone. The pace of new filings reflects growing public awareness of the litigation and an expanding pool of patients who have connected their injuries to the drug.

Novo Nordisk has filed motions to dismiss the lawsuits and to exclude testimony from plaintiffs’ causation experts, arguing that the company’s FDA-approved labeling was adequate and that prescribing physicians — not patients directly — were properly warned under the “learned intermediary” doctrine. Those motions remain pending.

A second MDL — MDL No. 3163 — was established in late 2025 specifically for vision loss claims, namely non-arteritic anterior ischemic optic neuropathy (NAION), a condition that can cause permanent blindness. That MDL had 146 pending claims as of July 1, 2026. A “science day” was held June 2, 2026, allowing the court to evaluate the scientific evidence on causation between GLP-1 drugs and NAION before ruling on expert witness eligibility.

Bellwether trials — small sets of representative test cases that help both sides assess litigation risk and drive settlement negotiations — are anticipated to begin in late 2026 or 2027 for both MDLs. No global settlement has been reached, and none is expected before bellwethers are resolved.

The July 2026 Twist: Novo Nordisk Sues Eli Lilly

In a development that underscores just how commercially contested the GLP-1 market has become, Novo Nordisk filed a lawsuit against Eli Lilly in July 2026, alleging false advertising. Novo Nordisk claims that Eli Lilly’s TV commercials for Zepbound — the competing GLP-1 weight-loss drug — deceptively compare low doses of Wegovy against higher doses of Zepbound to artificially inflate Zepbound’s apparent superiority in clinical outcomes.

Eli Lilly disputes the claim, saying its advertising is truthful and grounded in direct scientific evidence. The lawsuit has no direct bearing on the patient injury claims in MDLs 3094 and 3163, but it signals that the manufacturers themselves are now locked in aggressive legal combat — a backdrop that puts even more public and regulatory scrutiny on the entire GLP-1 drug class.

Who Qualifies for a Wegovy Lawsuit?

You may be eligible to file a Wegovy injury lawsuit if you:

• Took Wegovy (or another semaglutide or GLP-1 drug such as Ozempic, Zepbound, Trulicity, or Victoza) as prescribed
• Developed one of the serious gastrointestinal complications listed above — gastroparesis, bowel obstruction, ileus, pancreatitis, or gallbladder disease — during use or shortly after stopping the drug
• Required hospitalization, emergency care, or surgery because of those complications
• Were not adequately warned by Novo Nordisk about the risk of these specific injuries

Pre-existing gastrointestinal conditions do not automatically disqualify a claim, but they will be scrutinized carefully. If your condition demonstrably worsened or if GLP-1 use triggered a new acute episode, a claim may still be viable.

Patients who developed vision loss (NAION) linked to Wegovy or Ozempic should seek separate evaluation for the MDL 3163 track, which covers that injury category distinctly.

What Are These Cases Worth?

No Wegovy lawsuits have settled as of July 2026 — the litigation is still in early phases of discovery and pre-trial motions. That means there is no official settlement range to cite. However, personal injury attorneys working on GLP-1 cases have estimated that:

• Cases involving severe gastroparesis or bowel obstruction requiring surgery could be worth $100,000 to $500,000 or more
• Cases involving permanent disability — inability to tolerate solid foods, permanent feeding tube dependency, or total loss of digestive function — could reach $1 million or higher
• Vision loss cases (NAION with permanent blindness) represent the most catastrophic category, with potential values at the high end of the range

These figures are projections based on analogous pharmaceutical litigation — not confirmed Wegovy settlement values. The bellwether trials, when they occur, will be the first real data points on what juries think these cases are worth.

The Statute of Limitations: Why Timing Matters

Personal injury claims against pharmaceutical companies are subject to statutes of limitations — deadlines that vary by state but typically run two to three years from when the injury was discovered or reasonably should have been discovered. For Wegovy patients:

• If you were diagnosed with gastroparesis or bowel obstruction during or after Wegovy use, the clock on your claim may have started at that diagnosis
• If you were injured but didn’t connect your condition to the drug until recently — because doctors didn’t flag the connection — some states’ discovery rules may extend your deadline
• Claims against Novo Nordisk as a pharmaceutical company follow standard civil statute of limitations rules; there are no special government-entity notice requirements here

The practical message: if you believe you were injured by Wegovy and haven’t consulted an attorney, do it soon. The closer you get to whatever state deadline applies to you, the harder it becomes to properly build and file a claim.

What to Do If You Were Injured

If you took Wegovy and experienced serious gastrointestinal complications, these steps matter:

1. Preserve your medical records. Get full records from every provider who treated your GI injury — primary care, gastroenterologist, emergency room, surgeon. These are the evidentiary backbone of your case.
2. Keep your prescription documentation. Pharmacy records, prescription labels, and any written communications from Novo Nordisk or your prescribing physician about Wegovy’s risks should be retained.
3. Do not assume pre-existing conditions disqualify you. Have an attorney evaluate whether GLP-1 use contributed to or worsened your condition before making that call yourself.
4. Consult a pharmaceutical injury attorney. These claims are technically complex — they involve causation science, FDA regulatory history, and MDL procedural rules. An attorney who handles pharmaceutical injury cases or product liability claims will know whether your case has the documented injury profile the MDL requires.

Most pharmaceutical injury attorneys handling Wegovy claims work on contingency — meaning no upfront fees and no payment unless you recover. catastrophic injury claims and mass tort pharmaceutical litigation, attorney fees typically run 33–40% of the recovery on a contingency basis. If the case resolves through MDL global settlement — as most mass tort MDLs eventually do — fees are often capped lower by court order.

Looking Ahead

The Wegovy MDL will likely follow the arc of prior major pharmaceutical MDLs: years of pre-trial litigation, bellwether trials that reveal case strength and jury temperament, and eventually a global settlement process. The 3M earplug MDL (96,000 cases, $6 billion settlement) and Roundup MDL ($10 billion-plus in settlements) are the most comparable recent examples in scale and trajectory.

Novo Nordisk’s pattern of defending aggressively while filing its own litigation against competitors signals a company that believes it has a viable legal defense — and the resources to sustain years of litigation. For individual plaintiffs, that means joining the MDL sooner gives more time for the legal process to develop and for a settlement to materialize.

If you or someone in your family took Wegovy and suffered serious gastrointestinal complications, the litigation is active, the case count is growing, and attorney evaluations are free. Don’t wait for a settlement announcement to find out whether you qualify — by that point, your statute of limitations may have run.